
Sign up to save your podcasts
Or


Bioengineering is full of oversimplifications.
In this episode, I break down common myths that show up in research papers, startups, and even academic labs:
• “More power = more effect”
• “In vitro results translate directly to patients”
• “Reactive species are always harmful”
• “If it works once, it scales”
• “Plasma is just oxidation”
We’ll talk about dose-response behavior, mechanistic rigor, nonlinear biology, scaling challenges, and why systems thinking matters.
I’ve spent over a decade as a research professor and now run an R&D company focused on plasma systems for medical and environmental applications. This is a calm, technically grounded conversation about where bioengineering narratives often drift away from reality.
If you enjoy serious discussions about science without hype, this channel is for you.
By Gregory FridmanBioengineering is full of oversimplifications.
In this episode, I break down common myths that show up in research papers, startups, and even academic labs:
• “More power = more effect”
• “In vitro results translate directly to patients”
• “Reactive species are always harmful”
• “If it works once, it scales”
• “Plasma is just oxidation”
We’ll talk about dose-response behavior, mechanistic rigor, nonlinear biology, scaling challenges, and why systems thinking matters.
I’ve spent over a decade as a research professor and now run an R&D company focused on plasma systems for medical and environmental applications. This is a calm, technically grounded conversation about where bioengineering narratives often drift away from reality.
If you enjoy serious discussions about science without hype, this channel is for you.